MK-677: Oral Ghrelin Agonism and Around-the-Clock IGF-1

A Non-Peptide Ghrelin Receptor Agonist

MECHANISM OF ACTION

MK-677 (Ibutamoren) is a small-molecule, orally bioavailable agonist at the ghrelin receptor (GHSR-1a) — the same receptor targeted by injectable GHRPs like Ipamorelin and GHRP-6. Unlike those peptides, MK-677 is not a peptide at all; it is a synthetic spiroindoline-based compound designed specifically to survive oral administration and first-pass metabolism intact. Binding GHSR-1a on pituitary somatotrophs triggers growth hormone release through the same downstream calcium-signaling cascade as endogenous ghrelin, while also acting centrally in the hypothalamus.

Sustained, Non-Pulsatile GH Elevation

Where injectable secretagogues produce a single, discrete GH pulse per dose, MK-677's long half-life (~24 hours) means a single oral dose keeps the ghrelin receptor engaged continuously, producing a sustained elevation in both the amplitude and number of natural GH pulses across the full 24-hour cycle rather than one isolated spike. This distinguishes its pharmacokinetics from short-acting GHRPs and is the basis for once-daily oral dosing.

Downstream IGF-1 and Appetite Signaling

Growth hormone released via GHSR-1a activation drives hepatic IGF-1 production, the standard biomarker used to confirm response. Because the ghrelin receptor also mediates appetite and gastric motility in the hypothalamic arcuate nucleus, MK-677 reliably increases hunger — a mechanistic side effect shared with ghrelin itself, and one of the clearest ways MK-677's action differs in practice from the more selective injectable secretagogues like Ipamorelin.

Research Protocol Doses Reported in Published Literature

Research Disclaimer: Doses reported below are from published clinical and preclinical research protocols. MK-677 is not approved for human use by the FDA or any regulatory agency. This information is provided for research reference only and does not constitute a dosing recommendation. All doses above are reported from published research protocols. Refer to the cited studies in the Research section above for original source data.

Safety & Tolerability

MK-677's side-effect profile follows directly from its mechanism: because it activates the ghrelin receptor systemically and continuously (rather than in a brief pulse), the most consistently reported effects across trials are increased appetite, mild fluid retention/edema, and transient lower-extremity numbness or tingling in some subjects. These are considered mechanistic — the same receptor that drives GH release also drives hunger signaling in the hypothalamus. Human data: Human exposure includes multiple randomized, placebo-controlled trials, notably a 2-year study in adults over 60 (Nass et al., 2008) — among the longest continuous human safety datasets of any GH secretagogue discussed in this library. That trial reported a modest increase in fasting glucose and insulin resistance markers in the treatment group relative to placebo, without crossing into diagnosed diabetes; glucose monitoring is the most consistently recommended precaution in the literature. Regulatory status: Not approved for human use by the FDA or any regulatory agency for any indication; it remains an investigational compound sold as a research chemical. It has been evaluated in GH-deficiency, sarcopenia, and cachexia research programs without reaching approval. Contraindications commonly cited in research protocols include active malignancy (GH/IGF-1 elevation is a theoretical concern in hormone-sensitive or GH-sensitive tumor growth), pregnancy, and uncontrolled diabetes given the observed effect on insulin sensitivity.

Key Findings at a Glance

• MK-677 is one of the few growth hormone secretagogues with genuine randomized, placebo-controlled human trial data — including a 2-year study in healthy older adults, not just short pharmacokinetic studies. • A single oral dose produces a sustained rise in growth hormone and IGF-1 lasting roughly 24 hours, unlike the single discrete pulse produced by short-acting injectable GHRPs. • The best-known long-term trial (Nass et al., 2008) found MK-677 increased fat-free mass in older adults but did not improve physical function or strength outcomes over 2 years — a distinction often lost in casual discussion of the compound. • Appetite stimulation and mild fluid retention are the most consistently reported effects across trials, tracing directly back to MK-677's ghrelin-mimetic mechanism.

Reversal of Diet-Induced Catabolism

Murphy et al. (1998) demonstrated in a randomized, placebo-controlled trial that oral MK-677 reversed the negative nitrogen balance induced by a hypocaloric diet in healthy adults, with treated subjects maintaining nitrogen balance while placebo subjects did not. This was among the first human demonstrations that an orally active ghrelin mimetic could produce growth hormone and IGF-1 elevations sufficient to counteract a catabolic state — the finding that anchored later interest in sarcopenia and cachexia research. [Murphy MG, et al., 1998]

2-Year Trial in Healthy Older Adults

The most substantial human dataset comes from Nass et al. (2008), a randomized, double-blind, placebo-controlled trial in adults over 60 given MK-677 daily for 2 years. Fat-free mass increased significantly versus placebo, and IGF-1 levels rose into the young-adult reference range and stayed there for the full study duration. However, the trial found no significant improvement in measures of physical function, muscle strength, or insulin sensitivity — treated subjects also had a higher, though not statistically dangerous, incidence of increased fasting glucose and mild insulin resistance. This is the key nuance in MK-677's research record: body-composition changes reliably occur, but they have not translated into functional performance gains in controlled trials. [Nass R, et al., 2008]

Sleep Architecture

Because natural growth hormone secretion peaks during slow-wave sleep, and MK-677 sustains GH elevation across the sleep window specifically, several smaller studies have examined its effect on sleep quality. Findings suggest modest increases in REM sleep duration and subjective sleep quality in some cohorts, though data is far less extensive than the body-composition literature and effect sizes are inconsistent across studies.

MK-677 + CJC-1295 (no-DAC)

A common research pairing that combines MK-677's sustained, 24-hour ghrelin-receptor activation with a GHRH analog's direct stimulation of the pituitary's own GH-releasing pathway. The two act on distinct receptor systems (GHSR-1a vs GHRH-receptor), which is the typical rationale researchers cite for combining a secretagogue with a GHRH analog rather than stacking two secretagogues. No clinical trial has tested this specific combination directly; the rationale is mechanistic, extrapolated from each compound's individual pharmacology.

MK-677 + Ipamorelin

Because both compounds act at the same receptor (GHSR-1a), this pairing is mechanistically redundant rather than synergistic — MK-677 already keeps the receptor engaged around the clock, so adding a short-acting GHRP on top does not add a distinct pathway the way a GHRH analog does. Researchers who want an oral-only protocol sometimes use MK-677 alone rather than combining it with an injectable in the same GHSR-1a class.

Oral Absorption and a 24-Hour Half-Life

MK-677's defining pharmacokinetic feature is that it is orally bioavailable and long-acting — the property that separates it from every injectable secretagogue in this library. • Oral Tmax is approximately 30 minutes to 2 hours, with a terminal elimination half-life of approximately 24 hours, dramatically longer than Ipamorelin's ~2 hours or GHRP-6's ~1 hour. • Because of this long half-life, once-daily oral dosing maintains meaningfully elevated growth hormone and IGF-1 levels across the full 24-hour period rather than producing one discrete pulse, and IGF-1 in particular stays elevated between doses due to its own longer physiological half-life. • No injection or reconstitution is required — MK-677 is dosed as an oral capsule or solution, which is the practical basis for its popularity as a lower-friction alternative to injectable GH secretagogues.